A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Pirtobrutinib (LOXO-305) in Healthy Subjects
Latest Information Update: 09 Mar 2025
Price :
$35 *
At a glance
- Drugs Pirtobrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 28 Dec 2023 New trial record